By Fineline Cube 
Edding Genor Group Holdings Limited (HKG: 6998) announced that China’s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for GB268, a highly differentiated PD-1/CTLA-4/VEGF trispecific antibody, for a Phase Ib/II clinical trial in patients with locally advanced unresectable or metastatic breast cancer. The trial will specifically evaluate GB268 in both triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer subtypes.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA) |
| Approval Type | Investigational New Drug (IND) Application |
| Product | GB268 – PD-1/CTLA-4/VEGF trispecific antibody |
| Trial Phase | Phase Ib/II |
| Indication | Locally advanced unresectable or metastatic breast cancer |
| Subtypes | Triple-negative breast cancer (TNBC) and HR+/HER2-negative breast cancer |
| Approval Date | 2 July 2026 |
Drug Profile & Innovation
- Molecule Type: Trispecific antibody simultaneously targeting PD-1, CTLA-4, and VEGF pathways
- Therapeutic Rationale: Integrated approach combining immune checkpoint inhibition (PD-1/CTLA-4) with anti-angiogenic activity (VEGF)
- Differentiation: First-in-class trispecific design addressing multiple tumor microenvironment mechanisms simultaneously
- Development Stage: Advancing from Phase I monotherapy data to Phase Ib/II combination evaluation
- Innovation Status: Highly differentiated platform technology with potential applicability across multiple solid tumors
Phase I Clinical Data Highlights
| Parameter | Result | Significance |
|---|---|---|
| Maximum Tolerated Dose | Not reached at 30 mg/kg | Indicates wide therapeutic window |
| Dose-Limiting Toxicities (DLTs) | None observed up to 30 mg/kg | Excellent safety profile compared to standard checkpoint inhibitors |
| Antitumor Activity | Favorable results demonstrated | Promising efficacy signals warranting further development |
| Safety Profile | Favorable across dose escalation | Supports potential for combination regimens and higher dosing |
Clinical Trial Design & Strategic Focus
| Aspect | Details |
|---|---|
| Patient Population | Locally advanced unresectable or metastatic breast cancer |
| Key Subtypes | TNBC (aggressive, limited treatment options) and HR+/HER2- (largest breast cancer segment) |
| Trial Structure | Phase Ib/II seamless design enabling rapid dose optimization and efficacy evaluation |
| Therapeutic Gap | Addresses significant unmet needs in both subtypes, particularly TNBC with poor prognosis |
| Competitive Landscape | Novel trispecific approach differentiates from existing monospecific and bispecific antibodies |
Market Opportunity & Strategic Significance
| Factor | Impact |
|---|---|
| TNBC Market Need | Represents 15-20% of breast cancers with limited targeted therapy options |
| HR+/HER2- Prevalence | Accounts for ~65% of all breast cancer cases, largest therapeutic segment |
| Trispecific Platform Validation | Success would validate Edding Genor’s proprietary multispecific antibody technology |
| China Biotech Innovation | Demonstrates advancement beyond biosimilars to complex novel biologics |
| Global Potential | Trispecific approach could have international applicability if successful |
Forward Outlook
The NMPA IND approval positions Edding Genor to advance a potentially transformative therapy for two major breast cancer subtypes with substantial unmet medical needs. By simultaneously targeting three critical pathways—immune checkpoints PD-1 and CTLA-4, plus angiogenesis through VEGF—the company aims to overcome limitations of single-target approaches and improve outcomes for patients with aggressive disease.
The favorable Phase I safety profile, with no dose-limiting toxicities even at 30 mg/kg, suggests GB268 may offer a superior therapeutic index compared to existing checkpoint inhibitors. This could enable more aggressive dosing strategies and combination approaches while maintaining manageable toxicity profiles.
Success in this trial would not only address critical gaps in breast cancer treatment but also validate Edding Genor’s trispecific antibody platform for potential expansion into other solid tumor indications. The company plans to leverage its established clinical development capabilities and partnerships with leading Chinese oncology centers to accelerate patient enrollment and data generation.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and therapeutic potential. Actual results may differ due to risks including clinical trial outcomes, safety findings, competitive dynamics, and regulatory decisions.-Fineline Info & Tech